Treatment with oral ibudilast slows brain shrinkage in patients with primary progressive multiple sclerosis (PPMS), but not in those with secondary progressive MS (SPMS), according to results of a Phase 2b clinical trial.
According to the findings, this could be partially due to faster disease progression in untreated controls with PPMS.
The study, “Response to Treatment According to Progressive Disease Type: Analysis from a Phase II Progressive MS Trial of Ibudilast,” will be presented at the 2019 American Academy of Neurology (AAN) Annual Meeting, taking place May 4–10 in Philadelphia.
Andrew Goodman, MD, an investigator in the study and a professor at the University of Rochester School of Medicine and Dentistry, will discuss the data May 6 in the Platform Presentation 007: Session S12 Progressive Multiple Sclerosis.
Although PPMS and SPMS have been increasingly regarded as having more similarities than differences, whether they differ in response to treatment is still unclear.
To address this, scientists evaluated the impact of ibudilast on brain atrophy in these two types of progressive disease, as part of the SPRINT-MS (NCT01982942) trial. This 96-week, randomized, and double-blind study compared treatment with MediciNova’s investigational therapy with a placebo in 255 adults (ages 21–65) — 134 with PPMS and 121 with SPMS.
Participants took up to 100 mg of ibudilast in oral capsules per day.
Previously reported results from SPRINT-MS showed a 48% slowing in brain atrophy progression relative to placebo, as assessed by a measure called brain parenchymal fraction. This translates to a decrease of approximately 2.5 milliliters in brain tissue loss.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?